MOLOGEN AG
THE POWER OF IMMUNOTHERAPIES

QUARTERLY STATEMENT
AS OF 30 SEPTEMBER 2016

HIGHLIGHTS

- Capital increase and convertible bond after the reporting date: with gross proceeds of presumably €16.1 million in total
- Further implementation of "Next Level" strategy
- Advances in clinical studies with lead product lefitolimod (MGN1703)
- Progress in these trials affects financial result
- First anti-tumor data of the TLR9 agonist EnanDIM® in a murine model

KEY DATA (IFRS)

In million €	**Q3 2016**	**Q3 2015**	**Change %**	**Q1 – Q3 2016**	**Q1 – Q3 2015**	**Change %**
Revenues	0	0	-	0	0	-
Profit (loss) from operations (EBIT)	-4.5	-6.3	-29	-14.3	-13.3	8
Expense structure						
Personnel expenses	1.2	1.2	0	4.3	3.8	13
Research & Development expenses	3.5	5.2	-33	10.5	10.4	1
Earnings per share in € (basic)	-0.20	-0.28	-29	-0.63	-0.66	- 5
Cash flows from operating activities	-4.7	-4.3	9	-13.9	-9.0	54
	30 Sep 2016	**31 Dec 2015**	**Change %**			
Cash and cash equivalents	10.2	24.6	-59			
Shareholders' equity	4.9	19.5	-75			
Equity ratio	44 %	74 %	-41			
Total assets	11.3	26.4	-57			
Number of employees	61	66	-8			

CONTENTS

INTERIM MANAGEMENT REPORT

For the period from 1 January to 30 September 2016

- Successful capital increase and convertible bond after the reporting date: gross proceeds of presumably €16.1 million in total
- Further implementation of the “Next Level” strategy
- Continuation of clinical trials with immune surveillance reactivator (ISR) lefitolimod (MGN1703)
- Advances in studies affect financial result
- First anti-tumor data of the TLR9 agonist EnanDIM® in a murine model

In the third quarter of 2016, the focus was on the continued implementation of the “Next Level” strategy, which was announced in June. The clinical studies with the lead product lefitolimod (MGN1703) were also advanced. Progress was made in patient enrollment for the phase III IMPALA study as well as the other three studies with lefitolimod proceeding as planned.

This led to higher operating expenses in general with a slight increase of the expenses for research and development (R&D) to €10.5 million (9M 2015: €10.4 million). Due to the increase of operating expenses EBIT declined to €-14.3 million versus €-13.3 million in the first nine months of the previous year. In view of the plans to continue the current development program, a year-on-year increase in R&D expenses is expected for full-year 2016.

As of 30 September 2016, cash and cash equivalents totaled €10.2 million (31 December 2015: €24.6 million). Funds of a further €13.6 million were raised through the capital increase that was successfully completed after the reporting period. Furthermore, MOLOGEN will issue a convertible bond in November 2016. In total the company receives cash inflows of presumably €16.1 million.

Business performance

In the first nine months of the year, the main focus of the operational business was on the portfolio review as well as the development and subsequent implementation of the ‘‘Next Level’’ strategy. The new positioning of the company was announced in June 2016 and implementation began shortly thereafter.

Another focal point was the continuation of clinical studies with the lead product, the immune surveillance reactivator lefitolimod (MGN1703).

MOLOGEN presented preliminary data on the lefitolimod successor molecules EnanDIM® in a murine tumor model at a scientific congress in September in New York, U.S..

Summary of Next Level strategy: overview of main elements

- Strong product- and market-oriented focus on key projects, especially lefitolimod
- Portfolio to focus on
    - TLR9 product family with lead product lefitolimod and next-generation molecules EnanDIM®
    - Development of cell-based therapeutic vaccine MGN1601 to be shelved for the time being; subsequent possibly resumption if e.g. lefitolimod is successfully out-licensed
    - MIDGE® technology to be sold or spun off

- Preparation for potential market entry and out-licensing of lefitolimod
    - Production to be outsourced and upscaled
    - Consultancy company commissioned: activities related to out-licensing stepped up

- Corporate structures to be aligned with new strategy by end of 2016
    - In-house basic research to be discontinued; contract research and continuation of applied research where necessary
    - Decreased staffing levels in Production and Research divisions - specialists remain with company

Research and development (R&D)

In the first nine months of 2016, MOLOGEN advanced the clinical studies with its lead product, the immune surveillance reactivator (ISR) lefitolimod (MGN1703) in particular: the phase III IMPALA pivotal study in the indication colorectal cancer; the randomized IMPULSE clinical trial for lung cancer; the extended phase I TEACH study in the indication HIV and the phase I combination study with a checkpoint inhibitor.

R&D expenses

Expenses and investments in R&D amounted to €10.5 million in the first nine months of 2016 (9M 2015: €10.4 million). Activities focused on the two clinical trials with the ISR lefitolimod, IMPALA and IMPULSE.



Target portfolio

Implementation of the "Next Level" strategy results in the following portfolio:

Platform	Compound	Indications	PC	PH I	PH II	PH III	Study	Cooperation partners
DNA-based TLR9 agonists (ISR)	**Lefitolimod (MGN1703)**	▪ Metastatic colorectal cancer (mCRC)					IMPALA	-
		▪ Small cell lung cancer (SCLC)					IMPULSE	-
		▪ HIV					TEACH	Aarhus University Hospital
		▪ Advanced solid malignancies					Lefitolimod & ipilimumab	MD Anderson Cancer Center
	EnanDIM®	▪ Cancer / anti-infective therapies						
Therapeutic Vaccine (cell-line)	MGN 1601	▪ Renal cancer					On hold: backup compound	

ISR Immune Surveillance Reactivator I **PC** pre-clinical

In future, MOLOGEN's activities will center on continuing the four clinical trials with the immune surveillance reactivator (ISR) lefitolimod (MGN1703). As a result, most of the available funds will flow into the further development of lefitolimod (MGN1703) and the next generation compounds EnanDIM®.

Lefitolimod (MGN1703) is a cancer immunotherapy and MOLOGEN's most advanced TLR9 agonist, which is currently being tested in four clinical trials: the IMPALA, IMPULSE, TEACH studies as well as a combination study.

Pivotal study on colorectal cancer (IMPALA study)

Patient enrollment for the IMPALA study started in September 2014 and continued in the first nine months 2016. The IMPALA study is an international phase III multicentric, randomized, non-blinded, two-arm clinical trial. The aim of the study is to demonstrate that a "switch maintenance" therapy with the cancer immunotherapy lefitolimod (MGN1703) leads to a prolongation of the overall survival in patients with metastatic colorectal cancer. The primary endpoint is therefore overall survival (OS). The secondary endpoints include progression-free survival (PFS), tolerability, safety and quality of life (QoL).

Around 540 patients from approximately 120 centers in eight European countries, including the five largest European pharmaceutical markets, will participate in the study. Patient enrollment is set to be completed in the first quarter 2017. The study will be evaluated once a certain number of deaths (events) have occurred, which is currently estimated to be reached some 24 months after completion of patient enrollment.

In February 2016, the company announced that the Committee of Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had confirmed lefitolimod's MGN1703) development strategy with the pivotal IMPALA study by scientific advice.

Lung cancer study (IMPULSE study)

The enrollment of patients for the IMPULSE study started in March 2014 and was successfully concluded in October 2015 with the inclusion of the 100th patient. The primary endpoint of the IMPULSE study is overall survival. The study compares lefitolimod (MGN1703) with the best standard therapy available ("best standard of care“). The study included patients who are suffering from an extensive disease stage of small-cell lung cancer (SCLC) and whose tumors have responded to the standard first-line therapy with chemotherapeutics. Analysis of the phase II IMPULSE study in the indication small-cell lung cancer is set to start at the end of 2016. The initial findings are expected in the first half of 2017 and are to be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in June 2017.

HIV study (TEACH study)

The aim of the TEACH study is to determine whether lefitolimod (MGN1703) can activate the immune system in HIV patients so as to help deplete HIV reservoirs in HIV-positive pa-

tients. Aarhus University Hospital is conducting the trial in two hospital centers in Denmark and has already received funding from the American Foundation for AIDS Research (amfAR) for this purpose. MOLOGEN provides the medication, the ISR lefitolimod (MGN1703).

The collaboration with Aarhus University Hospital to conduct an early stage study with lefitolimod (MGN1703) to treat HIV patients (Human Immunodeficiency Virus, HIV) commenced in 2015. This was the first time lefitolimod (MGN1703) had been tested in patients suffering from a disease other than cancer. This could expand the potential range of applications of the product.

TEACH (**T**oll-like receptor 9 **e**nhancement of **a**ntiviral immunity in **c**hronic **H**IV infection) is a non-randomized interventional phase I/IIa study of lefitolimod (MGN1703) in HIV-infected patients. The primary endpoint of the study is the change in proportions of activated natural killer cells in the patients. Secondary study endpoints include, among others, collecting virological, immunological, pharmaco-dynamic and safety data.

MOLOGEN announced in March 2016 that the study would be continued in an extension phase. This means more patients can be included and receive longer treatment with lefitolimod (MGN1703). The decision is based on the broad immune system activation induced by the drug in patients as demonstrated by the pronounced increase in various immune markers. In conclusion, and consistent with the underlying hypothesis, lefitolimod (MGN1703) led to the activation of plasmacytoid dendritic cells (pDC), natural killer cells (NK) and T-cells in HIV positive patients during antiretroviral therapy (ART). Thus, lefitolimod (MGN1703) could play a role as an immune surveillance reactivator in the kick and kill concept of HIV eradication. Patients initially received treatment for a period of one month. The study protocol for the second phase provides for a longer treatment period with lefitolimod (MGN1703) of six months for 15 patients. Patient enrollment started at the end of June 2016 and the final study results are expected to be available in mid-2017.

Combination study ISR lefitolimod with checkpoint inhibitor Yervoy® in collaboration with MD Anderson Cancer Center

MOLOGEN's collaborator, MD Anderson Cancer Center, Texas (MD Anderson), enrolled the first patient in the combination study with a checkpoint inhibitor in July 2016. The collaboration comprises a phase I study with lefitolimod (MGN1703) in combination with the commercially available immunotherapy Yervoy® (ipilimumab) in patients with advanced solid malignancies. This is the first time ISR lefitolimod (MGN1703) is being evaluated in combination with a checkpoint inhibitor. If lefitolimod (MGN1703) enhances the efficacy of immune checkpoint blockades, and/or influences the side effects profile, this could expand

the potential range of applications of the product. The collaboration was initiated in January 2016 based on the idea that the combination of these two immunotherapies could have synergistic effects leading to a broader activation of the immune system. Combining various cancer immunotherapies has already shown promising results in other studies. This is a view also shared by MOLOGEN; other combination studies could follow depending on funding.

The aim of the study entitled "A Phase I Trial of Ipilimumab (immunotherapy) and MGN1703 (TLR Agonist) in Patients with Advanced Solid Malignancies“ is to initially find the highest tolerable dose of lefitolimod (MGN1703) that can be given in combination with Yervoy® (ipilimumab) to patients with advanced tumors. The safety of this drug combination will also be analyzed. Furthermore, this trial aims to evaluate the efficacy of the combination of these two immunotherapies in an extension phase. The combination of an immune surveillance reactivator with a checkpoint inhibitor is of particular interest: lefitolimod (MGN1703) is a TLR9 agonist that by reactivating immune surveillance can trigger the-body's own mechanisms to fight cancer on a targeted basis. Yervoy®, manufactured by Bristol-Myers Squibb Co., is a recombinant, human monoclonal antibody and immune checkpoint inhibitor, which is already approved to treat patients with unresectable or metastatic melanoma, among others.

MD Anderson is conducting the study in its cancer treatment center in Texas, US. Enrollment for the first approximately 50-60 patients started in July. MOLOGEN is providing the ISR lefitolimod (MGN1703) and funds the study.

EnanDIM®

EnanDIM® represents a new generation of immunoactivating TLR9 agonists and is therefore a follow-up compound to MOLOGEN TLR9 technology with longer patent protection.The EnanDIM® family of immune surveillance reactivators promise a broad activation of the immune system with a good tolerability profile. The mechanism of action of EnanDIM® molecules should facilitate their application in a range of cancer indications, either as a monotherapy or in combination with other targeted forms of treatment, such as checkpoint inhibitors, and other immunotherapeutic approaches. Moreover, compounds in the EnanDIM® family may also be used in the area of infectious diseases - such as HIV.

In the reporting period MOLOGEN presented data on lefitolimod and the EnanDIM®-technology in the context of several international scientific congresses, e.g. at the 2016 Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, U.S. or at the Keystone Symposia on Molecular and Cellular Biology Conference in Olympic Valley, U.S. .

With regard to EnanDIM® MOLOGEN presented preliminary anti-tumor data in a murine tumor modelat an international scientific congress. The pre-clinical in vivo data shows that EnanDIM® can reduce tumor growth and thus prolong survival. It has been shown previously that EnanDIM® molecules broadly activate immune cells in vitro and revealed no signs of toxicity after the administration of maximal feasible doses in vivo. These data constitute the next pre-clinical step towards a clinical development program of EnanDIM® in the treatment of cancer.

Financial performance and financial position

- Slight increase of R&D expenses to €10.5 million; EBIT down on same period of the prior year, at €-14.3 million due to increased operating costs
- Average cash utilized per month of €1.6 million (9M 2015: €1.3 million per month)
- Cash totals €10.2 million (31 December 2015: €24.6 million)

Overall, the company's financial performance and financial position developed according to plan in the first nine months of 2016. As of the reporting date, the cash and cash inflow from the cash capital increase through authorized capital carried out in October 2016 and the issuance of a convertible bond in November 2016 are expected to cover the financial needs of the company presumably until the fourth quarter of 2017.

Results of operations

In the first nine months of 2016, the revenues totaled €25 thousand and were therefore down on the same period of the prior year (9M 2015: €39 thousand). Other operating income amounted to €10 thousand (9M 2015: €5 thousand).

At €7.1 million, the cost of materials was €0.5 million higher than the previous year's figure (9M 2015: €6.6 million) and was primarily incurred in connection with running the IMPULSE and IMPALA clinical studies. In particular, this included costs for external services of €7.0 million (9M 2015: €6.5 million). (See note on page 16 1).

At €2.6 million, other operating expenses were lower than in the previous year (9M 2015: €2.8 million). (See note page 16 2). Higher costs for Business Development were countered by lower expenses for staff recruitment as well as decreased other expenses.

At €4.3 million in total, personnel expenses in the first nine months of the year were up on the figure of €3.8 million for the same period of 2015. Expenses for wages and salaries increased compared with the first nine months of 2015 due to the recruitment of additional

staff in clinical development over the second half of the previous year. In addition, non-recurring expenses were incurred in respect of decreases in staffing levels as part of the reorganization. Expenses from granting employee stock options were below the comparable previous year level.

The scheduled and unscheduled depreciation and amortization of assets were higher than in the previous year and amounted to €323 thousand (9M 2015: scheduled depreciation and amortization of €87 thousand). On account of the “Next Level” strategy change that was announced in the first half year of 2016 and the associated reorganization, property, plant and equipment and intangible assets which were no longer required were written off on an unscheduled basis.

Finance income decreased to €-0.2 thousand in the first nine months of 2016 due to the once again lower interest rates compared with the prior-year period (9M 2015: €2 thousand).

Of the total expenses, €10.5 million was used for research and development projects (9M 2015: €10.4 million) and was incurred primarily in relation to conducting clinical studies with lefitolimod. In addition, expenses increased to €0.33 million for business development, specifically for partnering and licensing preparation.

In the first nine months of 2016, EBIT was accordingly €1.0 million lower than in the previous year at €-14.3 million (9M 2015: €-13.3 million).



Net assets and financial position

Total assets have more than halved to €11.3 million (31 December 2015: €26.4 million). This is primarily due to cash burn and the net loss for the reporting period.

As of 30 September 2016, assets essentially comprised cash and cash equivalents amounting to €10.2 million (31 December 2015: €24.6 million). The decrease in assets is due to the cash utilized within the scope of operating activities; including outflows for in-

vestments and expenses for equity procurement, cash utilization stood at €14.4 million (9M 2015: €11.3 million).

In the reporting period, MOLOGEN was always in a position to comply with all its financial obligations.

At €80 thousand, the volume of the investments made in the first nine months of 2016 was lower than scheduled and unscheduled depreciation and amortization in the same period (€323 thousand). At €171 thousand, non-current assets as of 30 September 2016 were slightly below the level on the prior year's reporting date due to unscheduled depreciation and amortization (31 December 2015: €414 thousand).

Equity and liabilities are influenced by the reported equity in the amount of €4.9 million (31 December 2015: €19.5 million). The equity ratio has dropped to 44% (31 December 2015: 74%). The decrease is essentially due to the increased net loss.

As of 30 September 2016, current liabilities amounted to €6.3 million (31 December 2015: €6.9 million).

Other financial liabilities amounted to €18.3 million in total as of 30 September 2016 (31 December 2015: €21.7 million) and were essentially due to the conclusion of short-term service contracts for the IMPALA and IMPULSE studies that commenced in fiscal year 2014. The calculation of other financial liabilities was based on the assumed scheduled development of the company's business activities.

Liquidity development

In the first nine months of 2016, cash and cash equivalents used for operating activities in the amount of €13.9 million exceeded the prior year's value (9M 2015: €9.0 million) and were mainly committed to the further development of the IMPULSE and IMPALA studies; liabilities were also reduced by €1.1 million.

The outflows from investing activities decreased when compared with the prior-year period (9M 2016: €80 thousand; 9M 2015: €87 thousand).

The cash flows from financing activities amounted to €-0.45 million and are attributable to costs that were already incurred in relation with the capital measures that were conducted in the fourth quarter of 2016 (9M 2015: €26.1 million). A capital increase was carried out in the first half of the previous year.

Monthly cash consumption (taking into account incoming payments from sales as well as costs of equity capital procurement) amounted to an average of €1.6 million per month in the first nine months of 2016 and was therefore higher than the value of €1.3 million in the same period of the prior year.

Average monthly cash consumption



Supplementary report

On 23 September 2016, the Executive Board of MOLOGEN AG resolved, with the approval of the Supervisory Board, to implement a capital increase against cash contributions. The share capital of the company was increased from €22.6 million to €33.9 million through the issuance of 11,315,750 new bearer shares. The funds raised through the capital increase have greatly strengthened the company's share capital base and will fund the continued implementation of the "Next Level" strategy program. At a subscription price of €1.20 per share, the new shares were placed with existing shareholders by way of indirect subscription rights and with qualified investors as part of an international private placement that was significantly oversubscribed. The new shares carry full dividend rights from 1 January 2016.

Gross proceeds from the cash capital increase totaled €13.6 million. The capital increase was recorded in the relevant Commercial Register on 25 October 2016.

In addition, MOLOGEN will issue a convertible bond with a total nominal value of €2.54 million and an expected maturity up to 29 October 2024 to the Global Derivative Trading GmbH (GDT). The convertible bond offers fixed annual interest of 6% and the right of the investor to convert the convertible bond into 1,693,333 company shares under partial utilization of the conditional capital at a conversion price of €1.50. The convertible bond is to be issued in November 2016.

Due to the capital increase and issuance of a convertible bond the company receives gross proceeds of presumably €16.1 million.

Forecast, opportunities and risk report

Forecast report

The statements made in the Management Report for fiscal year 2015 on the objectives in the areas of research and development, cooperations and partnerships, earnings and liquidity development as well as personnel remain valid, in consideration of the “Next Level” strategy described in the interim report (cf. Annual Report 2015, page 51 et seq.).

Opportunities and risks report

The opportunities and risks, including their assessment, as presented in the Management Report for fiscal year 2015, essentially remain unchanged (cf. Annual Report 2015, page 52 et seq.).

In particular, the Executive Board's assessment of the financial risks remains unchanged.

Based on the new financial situation after the capital increase and the issuance of the convertible bond, the company's funding is now secured presumably up to the fourth quarter of 2017.

Interim Statement as of 30 September 2016

STATEMENT OF COMPREHENSIVE INCOME (IFRS)

for the period from 1 January to 30 September 2016

EUR'000	**Q3 2016**	**Q3 2015**	**Q1 – Q3 2016**	**Q1 – Q3 2015**
	unaudited	**unaudited**	**unaudited**	**unaudited**
Revenues	25	0	25	39
Other operating income	0	3	10	5
Cost of materials	-2,024	-4,037[(2)]	-7,111	-6,643[(1)]
Personnel expenses	-1,164	-1,158	-4,267	-3,775
Depreciation and amortization	-260	-35	-323	-87
Other operating expenses	-1,037	-1,122[(2)]	-2,641	-2,791[(1)]
Profit (loss) from operations	**-4,460**	**-6,349**	**-14,307**	**-13,252**
Finance costs	0	0	0	0
Finance income	0	0	0	2
Profit (loss) before taxes	**-4,460**	**-6,349**	**-14,307**	**-13,250**
Tax result	0	0	0	0
Profit (loss) for the period/ comprehensive income	**-4,460**	**-6,349**	**-14,307**	**-13,250**
Loss carried forward	-109,287	-87,415	-104,771	-84,235
Accumulated deficit	**-113,747**	**-93,764**	**-119,078**	**-97,485**
Basic earnings per share (in €)	**-0.20**	**-0.28**	**-0.63**	**-0.66**
Diluted earnings per share (in €)	**-**	-	**-**	-

([1]) Adjusted (change in presentation of expenses amounting to €243 thousand regarding clinical trials between cost of material and other operating expenses) pursuant to IAS 1.45 in conjunction with IAS 8.14 et seqq.

([2]) Adjusted (change in presentation of expenses amounting to €154 thousand regarding clinical trials between cost of material and other operating expenses) pursuant to IAS 1.45 in conjunction with IAS 8.14 et seqq.

STATEMENT OF FINANCIAL POSITION (IFRS)

as of 30 September 2016

EUR'000	30 Sep 2016 unaudited	31 Dec 2015 audited
ASSETS		
Non-current assets	**171**	**414**
Intangible assets	66	175
Property, plant and equipment	105	239
Current assets	**11,091**	**25,981**
Cash and cash equivalents	10,190	24,592
Trade receivables	0	0
Inventories	23	28
Other current assets	877	1,360
Income tax receivables	1	1
Total assets	**11,262**	**26,395**
EQUITY AND LIABILITIES		
Non-current liabilities	**5**	**6**
Deferred income	5	6
Current liabilities	**6,348**	**6,886**
Trade payables	5,336	6,390
Other current liabilities and deferred income	994	488
Liabilities to banks	18	8
Shareholders' equity	**4,909**	**19,503**
Issued capital	22,632	22,632
Capital reserves	101,355	101,642
Accumulated deficit	-119,078	-104,771
Total	**11,262**	**26,395**

STATEMENT OF CASH FLOWS (IFRS)

for the period from 1 January to 30 September 2016

EUR'000	Q1 – Q3 2016 unaudited	Q1 – Q3 2015 unaudited
Cash flows from operating activities		
Loss for the period before taxes	-14,307	-13,250
Depreciation and amortization of intangible assets and property, plant and equipment	323	87
Profit from disposal of intangible assets and property, plant and equipment	0	0
Other non-cash expenses and income	163	401
Change in trade receivables, inventories and other assets	488	-660
Change in trade payables and other liabilities	-538	4.389
Interest expenses/interest income	0	-2
Interest tax expenses/-income	0	0
Income tax payments	0	6
Net cash used in operating activities	**-13,871**	**-9,029**
Cash flows from investing activities		
Cash payments to acquire property, plant and equipment	-22	-81
Cash payments to acquire intangible assets	-58	-8
Interest received	0	2
Net cash used in investing activities	**-80**	**-87**
Cash flows from financing activities		
Cash proceeds from issuing shares	-452	26,095
Interest paid	0	0
Net cash used in financing activities	**-452**	**26,095**
Effect of exchange rate changes on cash	**1**	**0**
Total changes in cash and cash equivalents	**-14,402**	**16,979**
Cash and cash equivalents at the beginning of the period	**24,592**	**13,563**
Cash and cash equivalents at the end of the period	**10,190**	**30,542**

STATEMENT OF CHANGES IN EQUITY (IFRS)

as of 30 September 2016

EUR'000 except share data	**Issued Capital**		**Capital Reserves**	**Accumulated Deficit**	**Shareholder`s Equity**
	Number of ordinary shares	Share Capital			
As of 31 Dec 2014 (audited)	**16,973,626**	**16,974**	**80,559**	**-84,235**	**13,298**
Capital increase in exchange for cash contributions	5,657,875	5,658	20,437		**26,095**
Value of services rendered by employees (according to IFRS 2)			398		**398**
Loss for the period				-13,250	**-13,250**
Rounding difference			-1		**-1**
As of 30 Sep 2015 (unaudited)	**22,631,501**	**22,632**	**101,393**	**-97,485**	**26,540**
As of 31 Dec 2015 (audited)	**22,631,501**	**22,632**	**101,642**	**-104,771**	**19,503**
Capital increase in exchange for cash contributions			-452		**-452**
Value of services rendered by employees (according to IFRS 2)			165		**165**
Loss for the period				-14,307	**-14,307**
As of 30 Sep 2016 (unaudited)	**22,631,501**	**22,632**	**101,355**	**-119,078**	**4,909**

FINANCIAL CALENDAR 2017

22 March 2017
Full Year Report 2016

28 April 2017
Annual General Meeting

11 May 2017
Quarterly Statement
as of 31 March 2017

10 August 2017
Half-yearly Report
as of 30 June 2017

9 November 2017
Quarterly Statement
As of 30 September 2017

FOR FURTHER INFORMATION PLEASE CONTACT

Investor Relations & Corporate Communications
Phone +49 30 84 17 88-38
investor@mologen.com
www.mologen.com

DISCLAIMER

This information contains forward-looking statements based on current assumptions and estimates by the company management of MOLOGEN AG. Forward-looking statements are characterized by the use of words such as expect, intend, plan, predict, assume, believe, estimate, and similar formulations. These statements are not to be understood as in any way guaranteeing that these expectations will turn out to be accurate. Future performance and the results achieved by MOLOGEN AG depend on a number of risks and uncertainties and may therefore differ materially from the forward-looking statements. Many of these factors, such as the future economic environment and the behavior of competitors and others involved in the marketplace, are outside the control of MOLOGEN AG and cannot be accurately estimated in advance. MOLOGEN neither plans nor undertakes to update any forward-looking statements.

IMPRINT

Publisher
MOLOGEN AG
Fabeckstrasse 30, D-14195 Berlin
Tel.: +49 30 84 17 88-0
Fax: +49 30 84 17 88-50